Alnylam Pharmaceuticals Revenue | ALNY

Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.

Traditionally defined as follows:
Revenue = Price * Quantity of products

Revenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.^[1]

This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.

Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.

Annual Revenue Alnylam Pharmaceuticals

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007
3.71 B	2.25 B	1.83 B	1.04 B	844 M	493 M	220 M	74.9 M	89.9 M	47.2 M	41.1 M	50.6 M	47.2 M	66.7 M	82.8 M	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
3.71 B	41.1 M	726 M

Quarterly Revenue Alnylam Pharmaceuticals

2026-Q2	2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1	2010-Q3	2010-Q2
1.29 B	1.25 B	774 M	594 M	-	501 M	660 M	494 M	-	751 M	319 M	319 M	-	264 M	225 M	213 M	-	188 M	221 M	178 M	164 M	126 M	104 M	99.5 M	71.7 M	70.1 M	44.7 M	33.3 M	21 M	2.07 M	29.9 M	21.9 M	37.9 M	17.1 M	15.9 M	19 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-1.61 M	-1.14 M	-889 K	-	-467 K	-1.01 M	20.9 M	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
1.29 B	-1.61 M	240 M

References

Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).

Revenue of other stocks in the Biotechnology industry

Issuer	Revenue	Price	% 24h	Market Cap	Country
FSD Pharma HUGE	257 K	-	5743.5 %	$ 69.7 M	Canada
Cullinan Management CGEM	18.9 M	$ 16.5	-5.82 %	$ 994 M	USA
Happiness Biotech Group Limited HAPP	71.5 K	-	1.35 %	$ 17.8 M	China
Dynavax Technologies Corporation DVAX	277 M	-	-	$ 2.02 B	USA
AgeX Therapeutics AGE	130 K	-	-10.17 %	$ 12.2 K	USA
I-Mab IMAB	27.6 M	-	-	$ 866 M	China
Heron Therapeutics HRTX	155 M	$ 0.5	-0.24 %	$ 83.4 M	USA
Deciphera Pharmaceuticals DCPH	163 M	-	-	$ 2.18 B	USA
Alexion Pharmaceuticals, Inc. ALXN	6.07 B	-	-	$ 40.3 B	USA
INmune Bio INMB	50 K	$ 1.75	-1.13 %	$ 43.3 M	USA
Genfit SA GNFT	70.9 M	-	2.54 %	$ 160 B	France
Alpine Immune Sciences ALPN	58.9 M	-	-	$ 2.17 B	USA
ASLAN Pharmaceuticals Limited ASLN	3 M	-	-14.27 %	$ 1.7 M	Singapore
AstraZeneca PLC AZN	58.7 B	-	-	$ 96.9 B	Britain
CureVac N.V. CVAC	48.9 M	-	-	$ 867 M	Germany
EyeGate Pharmaceuticals, Inc. EYEG	12.1 K	-	-1.52 %	$ 24.7 M	USA
Abcam plc ABCM	362 M	-	-	$ 4.9 B	Britain
Midatech Pharma plc MTP	381 K	-	-18.52 %	$ 27.3 M	Britain
MorphoSys AG MOR	238 M	-	2.43 %	$ 254 M	Germany
Mirum Pharmaceuticals MIRM	521 M	$ 105.95	-5.9 %	$ 5.32 B	USA
Affimed N.V. AFMD	8.28 M	-	-34.95 %	$ 21.5 M	Germany
MannKind Corporation MNKD	349 M	$ 3.91	-4.87 %	$ 1.2 B	USA
MediciNova MNOV	410 K	$ 1.33	-0.75 %	$ 65.3 M	USA
Институт стволовых клеток человека ISKJ	1.08 B	-	-	-	Russia
AnPac Bio-Medical Science Co., Ltd. ANPC	12 M	-	-1.58 %	$ 28.1 M	China
Celyad Oncology SA CYAD	5 K	-	-	$ 12.5 M	Belgium
Berkeley Lights BLI	78.6 M	-	-7.31 %	$ 87 M	USA
Generation Bio Co. GBIO	19.9 M	-	-	$ 344 M	USA
IMV IMV	188 K	-	-	$ 13.1 M	Canada
Ayala Pharmaceuticals AYLA	692 K	-	-	$ 7.46 M	Israel
Cyclacel Pharmaceuticals CYCCP	43 K	-	-4.36 %	$ 27 M	USA
GlycoMimetics GLYC	10.8 M	-	9357.83 %	$ 1.01 B	USA
Advaxis ADXS	13 K	-	-9.65 %	$ 45.9 M	USA
Aeterna Zentaris AEZS	7.5 M	-	5.93 %	$ 314 M	Canada
Aeglea BioTherapeutics AGLE	886 K	-	-	$ 1.01 B	USA
Applied Genetic Technologies Corporation AGTC	325 K	-	-	$ 26.5 M	USA
AIkido Pharma AIKI	123 M	-	1.93 %	$ 17.4 M	USA
Aptinyx APTX	1 M	-	-39.0 %	$ 4.57 M	USA
Albireo Pharma ALBO	40.6 M	-	-0.23 %	$ 916 M	USA